Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

February 16, 2021

Study Completion Date

March 14, 2022

Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

Nivolumab

Specified Dose on Specified Days

Trial Locations (17)

2193

Local Institution - 0013, Parktown, Johannesburg

6045

Local Institution - 0011, Port Elizabeth

6530

Local Institution - 0012, George

13790

Broome Oncology, Johnson City

18840

Guthrie Medical Group Sayre, Sayre

35205

Alabama Oncology, Birmingham

59102

St Vincent Frontier Cancer Center, Billings

90017

Los Angeles Hematology Oncology Medical Group, Los Angeles

200347

Local Institution - 0003, Craiova

1040045

Local Institution - 0016, Tokyo

1358550

Local Institution - 0018, Koto-ku

4648681

Local Institution - 0017, Nagoya

5418567

Local Institution - 0023, Osaka

K7L 2V7

Local Institution - 0015, Kingston

L1G 2B9

Local Institution - 0014, Oshawa

M5G 2M9

Local Institution - 0001, Toronto

022328

Local Institution - 0006, Sector 2

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY